Oculus Innovative Sciences, Inc. Stock Nasdaq
Equities
US67575P2074
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
Financials (USD)
Sales 2024 * | 14.7M | Sales 2025 * | 17.9M | Capitalization | 2.48M |
---|---|---|---|---|---|
Net income 2024 * | -5M | Net income 2025 * | -3M | EV / Sales 2024 * | 0.17 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.14 x |
P/E ratio 2024 * |
-0.18
x | P/E ratio 2025 * |
-0.35
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
Managers | Title | Age | Since |
---|---|---|---|
Amy Trombly
CEO | Chief Executive Officer | 57 | 19-09-26 |
John Poggetto
DFI | Director of Finance/CFO | 53 | 01-12-31 |
Jerome Dvonch
DFI | Director of Finance/CFO | 56 | 20-09-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Amy Trombly
CEO | Chief Executive Officer | 57 | 19-09-26 |
Jay Birnbaum
BRD | Director/Board Member | 79 | 07-04-19 |
Director/Board Member | 64 | 18-09-18 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |